Risk factor analysis of Swedish Left Ventricular Assist Device (LVAD) patients

Granfeldt, Hans; Koul, Bansi; Wiklund, Lars; Peterzén, Bengt; Lönn, Urban; Babić, Ankica; Ahn, Henrik Casimir

doi:10.1016/s0003-4975(03)01016-6

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assumption is supported by data published by Russo et al 100 and Nativi et al 89 The same assumption has been made in previous economic analyses. 30,98 l In our base-case analysis < 1% of patients are alive supported by a VAD beyond 70 months.…”

Section: Model Assumptions -Transition Probabilitiessupporting

confidence: 82%

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model

Sutcliffe

Connock²,

Pulikottil-Jacob³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

Section: Model Assumptions -Transition Probabilitiessupporting

confidence: 82%

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model

Sutcliffe

Connock²,

Pulikottil-Jacob³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

“…Although there was a survival advantage demonstrated in the REMATCH study, the outcomes led many to question whether the increased length of life was worth the expense to both the patients and the health care system. Another factor is age, which has consistently been identified in multiple studies as a risk factor for decreased survival and increased adverse events after LVAD placement (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). However, these previous studies have significant limitations.…”

Section: Discussionmentioning

confidence: 99%

“…Older patients (age Ն70 years) are the largest potential group who could benefit from LVAD support, yet advanced age has consistently been identified as a risk factor for poor outcome (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). These studies have several limitations: 1) use of proven inferior technology (pulsatile devices); 2) registry data of LVADs in patients with diverse indications (i.e., failure to wean from cardiopulmonary bypass, deterioration while awaiting transplantation, and ongoing cardiogenic shock); and 3) data from a variety of mixed lowvolume and high-volume centers.…”

mentioning

confidence: 99%

Clinical Strategies and Outcomes in Advanced Heart Failure Patients Older Than 70 Years of Age Receiving the HeartMate II Left Ventricular Assist Device

Adamson

Stahovich

Chillcott

et al. 2011

Journal of the American College of Cardiology

110

View full text Add to dashboard Cite

show abstract

“…A similar rate was reported by Granfeldt in a report of a Swedish centre experience using a range of devices. 39 Right heart failure requiring right ventricular assist device (RVAD) support was reported in 5% of HeartMate and Novacor cases in the study that compared these devices, 14 and in 7% 21 to 12% 22 of other HeartMate series. Right heart failure requiring right ventricular assistance or exhibiting symptoms of severe dysfunction was reported in 21% (7/34) of HeartMate patients in one centre.…”

Section: Adverse Eventsmentioning

confidence: 99%

Evaluation of the ventricular assist device programme in the UK

Sharples¹,

Buxton²,

Caine³

et al. 2006

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

Risk factor analysis of Swedish Left Ventricular Assist Device (LVAD) patients

Cited by 11 publications

References 22 publications

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model

Clinical Strategies and Outcomes in Advanced Heart Failure Patients Older Than 70 Years of Age Receiving the HeartMate II Left Ventricular Assist Device

Evaluation of the ventricular assist device programme in the UK

Contact Info

Product

Resources

About